Neurocrine Biosciences Inc (NBIX)
Current ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 1,724,700 | 1,876,600 | 1,669,800 | 1,799,000 | 1,607,000 | 1,649,900 | 1,496,600 | 1,432,800 | 1,453,500 | 1,205,500 | 1,019,300 | 1,018,200 | 972,800 | 1,005,700 | 1,110,100 | 1,085,400 | 1,016,200 | 1,156,900 | 1,146,200 | 968,200 |
| Total current liabilities | US$ in thousands | 507,700 | 429,700 | 398,500 | 712,900 | 654,800 | 691,600 | 582,500 | 374,100 | 537,700 | 485,100 | 285,700 | 253,500 | 245,800 | 225,900 | 212,900 | 190,000 | 186,500 | 611,000 | 573,000 | 140,300 |
| Current ratio | 3.40 | 4.37 | 4.19 | 2.52 | 2.45 | 2.39 | 2.57 | 3.83 | 2.70 | 2.49 | 3.57 | 4.02 | 3.96 | 4.45 | 5.21 | 5.71 | 5.45 | 1.89 | 2.00 | 6.90 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,724,700K ÷ $507,700K
= 3.40
The current ratio of Neurocrine Biosciences Inc has shown fluctuations over the reported periods. It started at a high of 6.90 on March 31, 2020, indicating a strong ability to meet its short-term obligations with current assets. However, the ratio decreased significantly to 2.00 by June 30, 2020, but gradually improved to 5.45 by December 31, 2020. Throughout 2021, the current ratio remained relatively stable above 5, suggesting a healthy liquidity position.
In 2022, there was a slight decline in the current ratio, falling to 2.49 by September 30, and further decreasing to 2.45 by December 31. However, in the first half of 2023, the ratio increased to 3.83 by March 31, before falling again to 2.57 by June 30, reflecting some volatility in the company's short-term liquidity position.
By the end of 2024, the current ratio had improved to 3.40 on December 31. Overall, the trend in Neurocrine Biosciences Inc's current ratio indicates fluctuations in its ability to cover short-term obligations with current assets over the analyzed periods. The company should continue to monitor and manage its liquidity position to ensure it can meet its short-term financial commitments effectively.
Peer comparison
Dec 31, 2024